Sight Sciences Inc

SGHT remains in a Stage 2 advancing phase, underpinned by an active Lockout Rally that has driven price above the 9 and 21 EMAs on rising volume. The medium-term bias is bullish, supported by a HH/HL sequence off the March low, while the long-term trend stays intact. Short-term execution is favorable now under the Lockout Rally override, so participation at shallow pullbacks into the EMAs aligns with continuation dynamics.

• ↑Q2 2026 revenue $23.4M (+20% YoY) with 91% gross margin
• ↑Interventional dry eye segment at $2.7M (+704% YoY) across 176 accounts
• ↓Earnings yield deeply negative and net loss $4.4M despite 63% improvement